Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s share price fell 1.5% on Friday . The stock traded as low as $65.02 and last traded at $65.29, with a volume of 263,346 shares changing hands. The stock had previously closed at $66.28.

RARE has been the topic of several recent analyst reports. Morgan Stanley reiterated a “hold” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 8th. Credit Suisse Group AG reiterated a “buy” rating and set a $101.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 9th. Leerink Swann reiterated a “buy” rating and set a $85.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, July 15th. Canaccord Genuity reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, May 10th. Finally, Jefferies Group reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Sunday, July 17th. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $97.32.

The company’s market capitalization is $2.57 billion. The stock’s 50 day moving average price is $62.61 and its 200 day moving average price is $62.32.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.44) by $0.02. During the same quarter in the previous year, the firm posted ($0.83) earnings per share. On average, equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post ($5.93) EPS for the current fiscal year.

In related news, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction on Friday, July 15th. The stock was sold at an average price of $50.85, for a total value of $1,017,000.00. Following the completion of the transaction, the chief executive officer now directly owns 513,597 shares of the company’s stock, valued at approximately $26,116,407.45. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Sunil Agarwal sold 649 shares of the stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $52.68, for a total value of $34,189.32. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Ultragenyx Pharmaceutical stock. Ameriprise Financial Inc. increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 24.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 470,334 shares of the biopharmaceutical company’s stock after buying an additional 93,380 shares during the period. Ameriprise Financial Inc. owned 1.21% of Ultragenyx Pharmaceutical worth $52,762,000 as of its most recent filing with the SEC.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.